Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
about
FAM83A confers EGFR-TKI resistance in breast cancer cells and in miceThe role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agentsDuctal barriers in mammary epitheliumP53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cellsCell membrane modulation as adjuvant in cancer therapySrc family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK.CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness.Effects of ionizing radiation on biological molecules--mechanisms of damage and emerging methods of detectionBroad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancerTransforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts.Microdomains in the membrane landscape shape antigen-presenting cell function.Mechanisms by Which Pleiotropic Amphiphilic n-3 PUFA Reduce Colon Cancer RiskMapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma.RaftProt: mammalian lipid raft proteome database.Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells.Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locationsKrill oil extract suppresses cell growth and induces apoptosis of human colorectal cancer cells.Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil.Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models.Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro.Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma.Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibitionFibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of MetA targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cellsReduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.Lipid raft localization of epidermal growth factor receptor alters matrix metalloproteinase-1 expression in SiHa cells via the MAPK/ERK signaling pathway.The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.Nuclear EGFR as a molecular target in cancer.Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization.Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy.Acid sphingomyelinase mediates 50-Hz magnetic field-induced EGF receptor clustering on lipid raft.Measurement of Epidermal Growth Factor Receptor-Derived Signals Within Plasma Membrane Clathrin Structures.
P2860
Q24296333-FF0622F9-A3A1-487D-A6BE-88CB991F2C49Q24304487-F7C5FD94-4A4F-498B-A8E0-FD65BBA274C3Q27023960-40922B88-0CDE-4AD5-9D2A-A489834AEDBEQ27308938-E348299F-9CD9-4D39-BB7C-B9CFE13BE4BFQ27316587-DE76600C-8A4A-4F5F-9D28-B4416039F1E9Q28078167-38D4739F-A314-4346-8D1A-7B643104E533Q30424531-B78CAC66-0D97-4130-BD16-0437149A1523Q30424563-299F4F19-C084-46E8-ACD0-66D7C7975ABBQ30431290-E3734B4F-707F-4653-9964-A9CCBEC8CC56Q33767975-78DC8F9C-AA23-4CB5-87AC-E9B6E43B4F2BQ33768197-54FA8FE8-30BA-4DBC-883F-92422F854B6FQ34339468-3BD98C28-925E-45AF-9346-0D976A3F70AEQ34380974-CC1B516D-58A6-45B2-9BB5-A6B0D7852798Q34494043-F90D8CE5-0F8D-4C62-A9D5-B899C46515F1Q34949789-053354EE-3447-4159-B5F6-23622C098033Q35119830-31FA24CD-AF9F-466B-AF24-34539F9EF6C8Q35253880-86FF36E7-60CC-4987-8B11-542DE645C151Q35379875-23DE98DA-5D0A-4B90-B34C-FEEADDACAB86Q35831012-8B394E33-A762-4F30-994E-5F65E8E2E9DAQ36117370-B9252B1B-465D-4789-A900-A3BE193424F2Q36214091-3A7830B1-00CE-4089-BE6D-C817DD2C295EQ36312110-72BE9F7C-7FA9-4098-A0B1-3E439BB6C954Q36491391-065E8F36-90AA-4E5E-93A6-9E5EF4F382BEQ36514558-00A83F8F-13B2-490D-B4D5-160533EF7EE9Q36627192-109FDE92-9FF3-4A40-A8E9-6C6EE67B2C19Q36924414-B0FA805C-B9D7-43C2-B166-4906DF53832CQ37380746-674FC550-0F5C-4DB2-9235-C5CEABE7537FQ37581161-5C3544BD-63BB-46B7-8BE8-400AC47E9AD4Q37581972-129005C5-A9DC-4075-827B-FBD758ACECBDQ38083086-7D7EB7E5-2CED-44B3-A37D-97CC783A25CDQ38119635-BEBDCC98-22BB-407C-84E4-FD69C62EEE49Q38169157-00294353-9598-4877-AD38-BB436D2444EAQ38199643-D752EA19-429D-4E78-A972-0DA61E3D76B7Q38902585-47B00D39-E2AB-4264-B049-8BE721152C09Q38998238-6CF11E5F-1B46-4921-A9F8-C222AA80066CQ39200406-40927AFC-6E42-49F5-A7C6-B2B0A085E356Q39273308-F884EEF1-892C-4003-BF48-8929FEE8C3EDQ40526393-A536F4D6-2A92-4501-A398-06710F7E16E6Q43345499-5DC79025-A139-4514-8214-FA33D5A6400CQ47974736-3B2DAF40-B8B3-4338-8458-3DAC55930C02
P2860
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@ast
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@en
type
label
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@ast
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@en
prefLabel
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@ast
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@en
P2093
P2860
P356
P1476
Lipid raft localization of EGF ...... ine kinase inhibitor gefitinib
@en
P2093
Julie L Boerner
Kelly L Mueller
Mary E Irwin
Natacha Bohin
P2860
P304
P356
10.1002/JCP.22570
P577
2011-09-01T00:00:00Z